We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
- Recent VIR Stock Price: $12.66
- Yearly Gain for VIR stock: -52.55%
- Market Cap for VIR stock: $1.72B
- P/E Ratio for VIR stock: -3.16
Will VIR's stock price go up? Is there an accurate VIR stock forecast available?
TipRanks.com reports that Vir Biotechnology, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $17.80. The target pricing ranges from a high VIR forecast of $28 down to a low forecast of $13. Vir Biotechnology, Inc. (VIR)’s last closing stock price was $12.66 which would put the average price target at 40.60% upside.
In addition, TradingView issued a rating for VIR stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on VIR stock.
Other analysts covering VIR include:
- Michael Ulz of Morgan Stanley issued a Hold rating with the price target of $15 on 18 hours ago
- Eric Joseph of J.P. Morgan issued a Hold rating with the price target of $13 on 18 hours ago
- Alec Stranahan of Bank of America Securities issued a Hold rating with the price target of $14 on 18 hours ago
- Joseph Stringer of Needham issued a Buy rating with the price target of $19 on 18 hours ago
If you are wondering if VIR is a good stock to buy, here are 3rd party ratings for VIR stock:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 34% (84 out of 248)
What is the sentiment on the street regarding Vir Biotechnology, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for VIR stock: Bullish
- Blogger Consensus for VIR stock:
- Media Buzz for VIR stock: Sell
- Insider Signal for VIR stock: Buying
- Investor Sentiment for VIR stock: Negative
- Hedge Fund signal for VIR stock: High Risk
The stock market is extremely volatile, and you need to do your own research on VIR stock including scouring the social networks like VIR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VIR stock chart >>
Summary: Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
- Recent SRRK Stock Price: $9.83
- Yearly Gain for SRRK stock: 55.54%
- Market Cap for SRRK stock: $783.98M
- P/E Ratio for SRRK stock: -4.7
Will SRRK's stock price go up? Is there an accurate SRRK stock forecast available?
TipRanks.com reports that Scholar Rock Holding Corporation currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $29.00. The target pricing ranges from a high SRRK forecast of $30 down to a low forecast of $28. Scholar Rock Holding Corporation (SRRK)’s last closing stock price was $9.83 which would put the average price target at 195.02% upside.
In addition, TradingView issued a rating for SRRK stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on SRRK stock.
Other analysts covering SRRK include:
- Etzer Darout of BMO Capital issued a Buy rating with the price target of $29 on 1 day ago
- Andres Y. Maldonado of H.C. Wainwright issued a Buy rating with the price target of $30 on 1 day ago
- Allison Bratzel of Piper Sandler issued a Buy rating with the price target of $28 on 1 week ago
If you are wondering if SRRK is a good stock to buy, here are 3rd party ratings for SRRK stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 34% (84 out of 248)
What is the sentiment on the street regarding Scholar Rock Holding Corporation? (Current ratings compiled by TipRanks.com)
- News Sentiment for SRRK stock: Bearish
- Blogger Consensus for SRRK stock:
- Media Buzz for SRRK stock: Neutral
- Insider Signal for SRRK stock: Selling
- Investor Sentiment for SRRK stock: Positive
- Hedge Fund signal for SRRK stock: High Risk
The stock market is extremely volatile, and you need to do your own research on SRRK stock including scouring the social networks like SRRK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SRRK stock chart >>
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
- Recent ARWR Stock Price: $25.24
- Yearly Gain for ARWR stock: -27.89%
- Market Cap for ARWR stock: $3.13B
- P/E Ratio for ARWR stock: -5.97
Will ARWR's stock price go up? Is there an accurate ARWR stock forecast available?
TipRanks.com reports that Arrowhead Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $56.00. The target pricing ranges from a high ARWR forecast of $90 down to a low forecast of $31. Arrowhead Pharmaceuticals, Inc. (ARWR)’s last closing stock price was $25.24 which would put the average price target at 121.87% upside.
In addition, TradingView issued a rating for ARWR stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on ARWR stock.
Other analysts covering ARWR include:
- Jason Gerberry of Bank of America Securities issued a Buy rating with the price target of $54 on 2 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $90 on 2 days ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $55 on 2 days ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $50 on 1 week ago
If you are wondering if ARWR is a good stock to buy, here are 3rd party ratings for ARWR stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Arrowhead Pharmaceuticals, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARWR stock: Bullish
- Blogger Consensus for ARWR stock:
- Media Buzz for ARWR stock: Neutral
- Insider Signal for ARWR stock: Selling
- Investor Sentiment for ARWR stock: Negative
- Hedge Fund signal for ARWR stock: High Risk
The stock market is extremely volatile, and you need to do your own research on ARWR stock including scouring the social networks like ARWR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARWR stock chart >>
Summary: Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
- Recent MRUS Stock Price: $52.40
- Yearly Gain for MRUS stock: 129.22%
- Market Cap for MRUS stock: $3.47B
- P/E Ratio for MRUS stock: -20.15
Will MRUS's stock price go up? Is there an accurate MRUS stock forecast available?
TipRanks.com reports that Merus N.V. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $82.00. The target pricing ranges from a high MRUS forecast of $91 down to a low forecast of $67. Merus N.V. (MRUS)’s last closing stock price was $52.40 which would put the average price target at 56.49% upside.
In addition, TradingView issued a rating for MRUS stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on MRUS stock.
Other analysts covering MRUS include:
- John Newman of Canaccord Genuity issued a Buy rating with the price target of $67 on 1 day ago
- Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $88 on 1 day ago
- Etzer Darout of BMO Capital issued a Buy rating with the price target of $91 on 2 days ago
- Andrew Berens of Leerink Partners issued a Buy rating with the price target of $88 on 6 days ago
If you are wondering if MRUS is a good stock to buy, here are 3rd party ratings for MRUS stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (84 out of 248)
What is the sentiment on the street regarding Merus N.V.? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRUS stock: Bullish
- Blogger Consensus for MRUS stock:
- Media Buzz for MRUS stock: Sell
- Insider Signal for MRUS stock: Selling
- Investor Sentiment for MRUS stock: Positive
- Hedge Fund signal for MRUS stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on MRUS stock including scouring the social networks like MRUS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRUS stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
